Stock data
Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc. (CTNM) reported net income of -US$59.98M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$68.06M | -US$59.98M | — |
| 2024 | US$0.00M | — | -US$50.89M | -US$42.26M | — |
| 2023 | US$50.00M | — | US$16.08M | US$22.72M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$15.15M | — |
| 2026-03-31 | — | -US$14.46M | — |
| 2025-12-31 | — | -US$15.16M | — |
| 2025-09-30 | — | -US$12.79M | — |
| 2025-06-30 | — | -US$16.04M | — |
| 2025-03-31 | — | -US$15.99M | — |
| 2024-12-31 | — | -US$14.56M | — |
| 2024-09-30 | US$0.00M | -US$10.27M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.